187 related articles for article (PubMed ID: 16962488)
1. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P
Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488
[TBL] [Abstract][Full Text] [Related]
2. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
3. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
4. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
Dall'era MA; Hosang N; Konety B; Cowan JE; Carroll PR
J Urol; 2009 Apr; 181(4):1622-7; discussion 1627. PubMed ID: 19230923
[TBL] [Abstract][Full Text] [Related]
5. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
Kane CJ; Bassett WW; Sadetsky N; Silva S; Wallace K; Pasta DJ; Cooperberg MR; Chan JM; Carroll PR
J Urol; 2005 Mar; 173(3):732-6. PubMed ID: 15711258
[TBL] [Abstract][Full Text] [Related]
6. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
[TBL] [Abstract][Full Text] [Related]
8. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
Ryan CJ; Elkin EP; Cowan J; Carroll PR
Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446
[TBL] [Abstract][Full Text] [Related]
9. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE.
Cooperberg M; Lubeck DP; Penson D; Mehta SS; Carroll PR; Kane CJ
J Urol; 2003 Sep; 170(3):905-8. PubMed ID: 12913727
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiologic indicators of adenocarcinoma of the prostate. Results on 436 patients].
Arrizabalaga Moreno M; García González JI; Diez Rodríguez JM; Esteban Artiaga R; Castro Pita M; Navarro Sebastian J; Mora Durbán M; Paniagua Andrés P
Actas Urol Esp; 1997 Oct; 21(9):852-61. PubMed ID: 9471868
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
12. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
Cooperberg MR; Broering JM; Litwin MS; Lubeck DP; Mehta SS; Henning JM; Carroll PR;
J Urol; 2004 Apr; 171(4):1393-401. PubMed ID: 15017184
[TBL] [Abstract][Full Text] [Related]
13. Explaining the race difference in prostate cancer stage at diagnosis.
Jones BA; Liu WL; Araujo AB; Kasl SV; Silvera SN; Soler-Vilá H; Curnen MG; Dubrow R
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2825-34. PubMed ID: 18829446
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
15. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
16. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor.
Boorjian S; Cowan JE; Konety BR; DuChane J; Tewari A; Carroll PR; Kane CJ;
J Urol; 2007 Mar; 177(3):883-7; discussion 887-8. PubMed ID: 17296367
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
18. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor.
Cooperberg MR; Lubeck DP; Grossfeld GD; Mehta SS; Carroll PR
J Urol; 2002 Aug; 168(2):491-5. PubMed ID: 12131295
[TBL] [Abstract][Full Text] [Related]
19. Changing nature of high risk patients undergoing radical prostatectomy.
Kane CJ; Presti JC; Amling CL; Aronson WJ; Terris MK; Freedland SJ;
J Urol; 2007 Jan; 177(1):113-7. PubMed ID: 17162017
[TBL] [Abstract][Full Text] [Related]
20. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]